|
1
|
Folkman J: Fundamental concepts of the
angiogenic process. Curr Mol Med. 3:643–651. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrara N: Vascular endothelial growth
factor: basic science and clinical progress. Endocr Rev.
25:581–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Senger DR, Galli SJ, Dvorak AM, Perruzzi
CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid.
Science. 219:983–985. 1983. View Article : Google Scholar
|
|
6
|
Shibuya M: Structure and function of
VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct
Funct. 26:25–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
8
|
Cook KM and Figg WD: Angiogenesis
inhibitors: current strategies and future prospects. CA Cancer J
Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Guidi AJ, Dvorak HF, Senger DR, Connolly JL and Schnitt SJ:
Expression of vascular permeability factor (vascular endothelial
growth factor) and its receptors in breast cancer. Hum Pathol.
26:86–91. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Linderholm B, Grankvist K, Wilking N,
Johansson M, Tavelin B and Henriksson R: Correlation of vascular
endothelial growth factor content with recurrences, survival, and
first relapse site in primary node-positive breast carcinoma after
adjuvant treatment. J Clin Oncol. 18:1423–1431. 2000.
|
|
11
|
Teng LS, Jin KT, He KF, Wang HH, Cao J and
Yu DC: Advances in combination of antiangiogenic agents targeting
VEGF-binding and conventional chemotherapy and radiation for cancer
treatment. J Chin Med Assoc. 73:281–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Teng LS, Jin KT, He KF, Zhang J, Wang HH
and Cao J: Clinical applications of VEGF-trap (aflibercept) in
cancer treatment. J Chin Med Assoc. 73:449–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jin K, He K, Teng F, Li G, Wang H, Han N,
Xu Z, Cao J, Wu J, Yu D and Teng L: FP3: a novel VEGF blocker with
antiangiogenic effects in vitro and antitumour effects in vivo.
Clin Transl Oncol. 13:878–884. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang M, Zhang J, Yan M, Li H, Yang C and
Yu D: Recombinant anti-vascular endothelial growth factor fusion
protein efficiently suppresses choridal neovascularization in
monkeys. Mol Vis. 14:37–49. 2008.
|
|
15
|
Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B
and Li H: The pharmacology study of a new recombinant human VEGF
receptor-fc fusion protein on experimental choroidal
neovascularization. Pharm Res. 26:204–210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang M, Zhang J, Yan M, Luo D, Zhu W,
Kaiser PK and Yu DC; KH902 Phase 1 Study Group: A phase 1 study of
KH902, a vascular endothelial growth factor receptor decoy, for
exudative age-related macular degeneration. Ophthalmology.
118:672–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin K, He K, Han N, Li G, Wang H, Xu Z,
Jiang H, Zhang J and Teng L: Establishment of a PDTT xenograft
model of gastric carcinoma and its application in personalized
therapeutic regimen selection. Hepatogastroenterology.
58:1814–1822. 2011.PubMed/NCBI
|
|
18
|
Jin K, Li G, Cui B, Zhang J, Lan H, Han N,
Xie B, Cao F, He K, Wang H, Xu Z, Teng L and Zhu T: Assessment of a
novel VEGF targeted agent using patient-derived tumor tissue
xenograft models of colon carcinoma with lymphatic and hepatic
metastases. PLoS One. 6:e283842011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang J, Frischer JS, New T, Kim ES, Serur
A, Lee A, Kadenhe-Chiwishe A, Pollyea DA, Yokoi A, Holash J,
Yancopoulos GD, Kandel JJ and Yamashiro DJ: TNP-470 promotes
initial vascular sprouting in xenograft tumors. Mol Cancer Ther.
3:335–343. 2004.PubMed/NCBI
|
|
20
|
Holash J, Davis S, Papadopoulos N, Croll
SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe
E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ,
Yancopoulos GD and Rudge JS: VEGF-Trap: a VEGF blocker with potent
antitumor effects. Proc Natl Acad Sci USA. 99:11393–11398. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roskoski R Jr: Vascular endothelial growth
factor (VEGF) signaling in tumor progression. Crit Rev Oncol
Hematol. 62:179–213. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Borgström P, Gold DP, Hillan KJ and
Ferrara N: Importance of VEGF for breast cancer angiogenesis in
vivo: implications from intravital microscopy of combination
treatments with an anti-VEGF neutralizing monoclonal antibody and
doxorubicin. Anticancer Res. 19:4203–4214. 1999.PubMed/NCBI
|
